Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Hemophilia Treatment Market – A Significant Management for Hemophilic Patients

Hemophilia, a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor, factor VIII. There are around 13 types of clotting factors that work with blood platelets to help the clotting. There are three forms of hemophilia - A, B, and C. Hemophilia A is the most common form and is caused due to deficiency in factor VIII. Hemophilia B occurs due to deficiency of factor IX and Hemophilia C is caused due to factor XI deficiency.

Novel product launches by market players in the hemophilia treatment are expected to boost growth of the market over the forecast period. For instance, in June 2019, Novo Nordisk received marketing authorization from the European Commission for ‘Esperoct’ in Europe. Esperoct is the brand name for turoctocog alfa pegol, N8-GP, indicated for surgical procedures in adolescents and adults with hemophilia A (congenital factor VIII deficiency). Moreover, in April 2019, Roche Products India Pvt. Ltd launched hemophilia A drug Emicizumab, branded as Hemlibra in India. It is indicated for prophylactic treatment for reducing frequency of bleeding episodes in patients with hemophilia A, through Factor VIII inhibitors.

Furthermore, increasing government initiatives to promote awareness about hemophilia treatment among the populace is expected to propel growth of the market over the forecast period. For instance, the National Bleeding Authority (NBA) provides funding to AHCDO (Australian Hemophilia Center Directors’ Organization) for treatment and management of hemophilia A (Factor VIII Deficiency) in Australia.

The global hemophilia treatment market size was valued at US$ 11,474.3 million in 2018, and is expected to exhibit a CAGR of 5.9% over the forecast period (2019-2027).

Figure 1. Global Hemophilia Treatment Market Value (US$ Mn), by Region, 2018

Hemophilia Treatment  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Rising cases of bleeding disorders is expected to boost growth of the global hemophilia treatment market

The global hemophilia treatment market is expected to witness significant growth owing to rising incidence of hemophilia or bleeding disorders. For instance, according to the Australian Bleeding Disorders Registry, in 2015, there were around 4,941 patients who suffered from common hereditary bleeding disorders, out of which 2,301 patients were diagnosed with hemophilia A, and 548 patients were diagnosed with hemophilia B in Australia. Thus, increasing prevalence of hemophilia is expected to drive demand for hemophilia treatment over the forecast period. Moreover, increasing demand for efficient therapeutics for treatment of factor VIII deficiency from emerging economies such as India is expected to drive the market growth over the forecast period. For instance, according to the World Federation of Hemophilia’s 2017 statistics, in India, around 18,353 people were diagnosed with hemophilia in 2016.

Figure 2. Global Hemophilia Treatment Market Share (%), by Product Type, 2019 and 2027

Hemophilia Treatment  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Increasing healthcare expenditure and reimbursement policies in respective countries or regions are expected to drive the market growth

North America is projected to hold a dominant position in the global hemophilia treatment market owing to increasing strategic partnerships and collaborations, which is expected to drive growth of the North America market growth over the forecast period. For instance, in April 2014, Biogen, Inc. signed a license agreement with Amunix Operating Inc., a California-based biotechnology company, for research and development of novel, fully-recombinant Factor VIII products with improved therapeutic properties. Under the license agreement, Biogen is focused on development of XTENylated Factor VIII products for treatment of factor VIII deficiency.

Moreover, Asia Pacific is expected to witness the second largest growth in the global hemophilia treatment market owing to rising favorable reimbursement policies for hemophilia treatment in economies such as China. For instance, according to the report published by the Chinese Ministry of Health in 2012, outpatient hemophilia treatment is covered by health insurance schemes in over 80% of the cities in China. Moreover, annual reimbursement is usually accounted below US$ 16,000.

Key Players

Major players operating in the global hemophilia treatment market include Takeda Pharmaceutical Co., Ltd., Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, F. Hoffmann-La Roche AG.

Hemophilia, a factor VIII deficiency, is a genetic disorder that is caused by the absence of the factor VIII clotting protein. Moreover, it is genetically passed down to the offspring and according to the National Hemophilia Foundation, in 2019 about 1/3 cases of factor VIII deficiency occurred due to spontaneous mutation in the gene of the parents. Rising incidence and prevalence of hemophilic disorders are expected to boost growth of the market over the forecast period. This has led to product launches by key players to fulfill the unmet needs of consumers. Favorable regulatory scenarios and guidelines for the product launches and treatment are other factors that are expected to propel growth of the market over the forecast period.

Furthermore, adoption of inorganic growth strategies such as collaborations by market players to develop novel therapies for treatment are expected to fuel growth of the hemophilia treatment market. For instance, in July 2019, Sangamo Therapeutics, Inc., a genomic medicine company, and Pfizer, Inc. announced updated results from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A.

Market Dynamics

The hemophilia treatment market is expected to witness significant growth over the forecast period owing to increasing number of hemophilic or factor VIII deficiency cases. For instance, according to the World Federation of Hemophilia, around 18,353 people in India suffered from hemophilia, and 15,218 people were diagnosed with hemophilia A in 2016, out of which around 83.0% had factor VIII deficiency.  Moreover, according to the World Federation of Hemophilia’s reports published in 2017, there were around 10,000 patients with hemophilia A in Brazil.

Product approvals by regulatory authorities are expected to drive growth of hemophilia treatment market over the forecast period. For instance, in 2016, the U.S. Food and Drug Administration approved Kedrion’s Koate Double Viral Inactivation (DVI) Antihemophilic Factor (human) with Mix2Vial, for treatment of factor VIII deficiency. Moreover, in February 2019, the U.S. Food and Drug Administration approved the biologics license application of Novo Nordisk’s long-acting recombinant factor VIII product, N8-GP Turoctocog alfa pegol (Esperoct), for treatment and prevention of hemophilia A.

Market players are also focused on adopting inorganic growth strategies such as acquisitions which is expected to fuel the market growth over the forecast period. For instance, in 2018, CSL Behring acquired a China-based plasma-derived therapies manufacturer, Wuhan Zhong Yuan Rui De Biological Products Co. Ltd. from Humanwell Healthcare Group Co. Ltd. The acquisition has expanded CSL’s presence in China’s domestic plasma fractionation market. It has also enabled CSL to expand their commercial footprint and contribute their expertise for benefit of patients with rare diseases in China.

Key features of the study:

  • This report provides in-depth analysis of the hemophilia treatment market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2019 -2027), considering 2018 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global hemophilia treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as part of this study include Takeda Pharmaceutical Co., Ltd., Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, F. Hoffmann-La Roche AG.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future product launches, technology upgradation, market expansion, and marketing tactics
  • The global hemophilia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the hemophilia treatment market

Detailed Segmentation:

  • Global Hemophilia treatment market, By Product Type:
    • Plasma Derived Coagulation Factor Concentrates
    • Recombinant Coagulation Factor Concentrates
    • Antifibrinolytic Agents
    • Desmopressin
  • Global Hemophilia treatment market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Hemophilia treatment market, By Region:
    • North America
      • By Product Type:
        • Plasma Derived Coagulation Factor Concentrates
        • Recombinant Coagulation Factor Concentrates
        • Antifibrinolytic Agents
        • Desmopressin
      • By Disease Indication:
        • Hemophilia A
        • Hemophilia B
        • Hemophilia C
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Product Type:
        • Plasma Derived Coagulation Factor Concentrates
        • Recombinant Coagulation Factor Concentrates
        • Antifibrinolytic Agents
        • Desmopressin
      • By Disease Indication:
        • Hemophilia A
        • Hemophilia B
        • Hemophilia C
        •  
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Product Type:
        • Plasma Derived Coagulation Factor Concentrates
        • Recombinant Coagulation Factor Concentrates
        • Antifibrinolytic Agents
        • Desmopressin
      • By Disease Indication:
        • Hemophilia A
        • Hemophilia B
        • Hemophilia C
        •  
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product Type:
        • Plasma Derived Coagulation Factor Concentrates
        • Recombinant Coagulation Factor Concentrates
        • Antifibrinolytic Agents
        • Desmopressin
      • By Disease Indication:
        • Hemophilia A
        • Hemophilia B
        • Hemophilia C
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Pakistan
        • Rest of Asia Pacific
    • Middle East
      • By Product Type:
        • Plasma Derived Coagulation Factor Concentrates
        • Recombinant Coagulation Factor Concentrates
        • Antifibrinolytic Agents
        • Desmopressin
      • By Disease Indication:
        • Hemophilia A
        • Hemophilia B
        • Hemophilia C
        •  
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product Type:
        • Plasma Derived Coagulation Factor Concentrates
        • Recombinant Coagulation Factor Concentrates
        • Antifibrinolytic Agents
        • Desmopressin
      • By Disease Indication:
        • Hemophilia A
        • Hemophilia B
        • Hemophilia C
        •  
      • By Country:
        • North Africa
        • Central Africa
        • South Africa
  • Company Profiles
    • Baxter International, Inc*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Sanofi S.A.
    • Octapharma AG
    • Swedish Orphan Biovitrum AB
    • Biogen Inc.
    • Bayer AG
    • CSL Behring
    • Pfizer, Inc.
    • Kedrion
    • Novo Nordisk A/S
    • Bayer AG
    • Sanofi S.A.
    • Octapharma AG
    • Swedish Orphan Biovitrum AB,

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Disease Indication
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Guidelines
    • Regulatory Scenario
    • Merger & Acquisitions
    • Product Launch
    • Epidemiology
    • Pipeline Analysis
    • New Product Launches
    • List of Approved Products
    • Pest Analysis
  4. Global Hemophilia Treatment Market, By Product Type, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Recombinant Coagulation Factor
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Plasma Derived Coagulation Factor
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Antifibrinolytic Agents
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Desmopressin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  5. Global Hemophilia Treatment Market, By Disease Indication, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hemophilia A
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Hemophilia B
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Hemophilia C
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Hemophilia Treatment Market, By Region, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2016 and 2026 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  7. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Takeda Pharmaceutical Co., Ltd.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Sanofi S.A.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Octapharma AG
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Swedish Orphan Biovitrum AB
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Baxter International Inc.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Biogen Inc.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Bayer AG
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • CSL Behring
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Ferring B.V.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Pfizer, Inc.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Kedrion
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Novo Nordisk A/S
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • F. Hoffmann-La Roche AG
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
    • Analyst Views
  8. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 35 market data tables and 21 figures on "Hemophilia Treatment Market - Global forecast to 2027”.

Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner